Serpin
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Serpin"
.

Figure 1: Recent serpin structures: the structure of a domain swapped antithrombin dimer reveals the likely physiological mechanism of serpin polymerisation.1

Serpins are a group of proteins with similar structures that were first identified as a set of proteins able to inhibit proteases. The name serpin is derived from this activity - serine protease inhibitors.2

The first members of the serpin superfamily to be extensively studied were the human plasma proteins antithrombin and antitrypsin, which play key roles in controlling blood coagulation and inflammation, respectively. Initially, research focused upon their role in human disease: antithrombin deficiency results in thrombosis and antitrypsin deficiency causes emphysema. In 1980 Hunt and Dayhoff made the surprising discovery that both these molecules share significant amino acid sequence similarity to the major protein in chicken egg white, ovalbumin, and they proposed a new protein superfamily.3 Over 1000 serpins have now been identified, these include 36 human proteins, as well as molecules in plants, fungi, bacteria, archaea and certain viruses.456 Serpins are thus the largest and most diverse family of protease inhibitors.7

While most serpins control proteolytic cascades, certain serpins do not inhibit enzymes, but instead perform diverse functions such as storage (ovalbumin, in egg white), hormone carriage proteins (thyroxine-binding globulin, cortisol binding globulin) and tumor suppressor genes (maspin). The term serpin is used to describe these latter members as well, despite their noninhibitory function.8

As serpins control processes such as coagulation and inflammation, these proteins are the target of medical research. However, serpins are also of particular interest to the structural biology and protein folding communities, because they undergo a unique and dramatic change in shape (or conformational change) when they inhibit target proteases.9 This is unusual - most classical protease inhibitors function as simple "lock and key" molecules that bind to and block access to the protease active site (see for example, bovine pancreatic trypsin inhibitor). While the serpin mechanism of protease inhibition confers certain advantages, it also has drawbacks and serpins are vulnerable to mutations that result in protein misfolding and the formation of inactive long chain polymers (serpinopathies; Figure 1).10111 Serpin polymerisation reduces the amount of active inhibitor, as well as accumulation of serpin polymers causing cell death and organ failure. For example, the serpin antitrypsin is primarily produced in the liver, and antitrypsin polymerisation causes liver cirrhosis.11 Understanding serpinopathies also provides insights on protein misfolding in general, a process common to many human diseases, such as Alzheimer’s and CJD.10

content

Contents

Cross class inhibitors

Figure 2: The X-ray crystal structure of the archetypal serine protease chymotrypsin (pdb code 4CHA).12 The three catalytic residues (His 57, Asp 102 and Ser 195) are labeled.

Most inhibitory serpins target chymotrypsin-like serine proteases (see Table 1 and Figure 2). These enzymes are defined by the presence of a nucleophilic serine residue in their catalytic site. Examples include thrombin, trypsin and human neutrophil elastase.13

Some serpins inhibit other classes of protease and are termed "cross class inhibitors". Most notably a number of such serpins have been shown to target cysteine proteases. These enzymes differ from serine proteases in that they are defined by the presence of a nucleophilic cysteine residue, rather than a serine residue, in their catalytic site.14 Nonetheless, the enzymatic chemistry is similar, and serpins most likely inhibit both classes of enzyme in a similar fashion.15

Examples of cross class inhibitory serpins include squamous cell carcinoma antigen 1 (SCCA-1) and the avian serpin myeloid and erythroid nuclear termination stage specific protein (MENT) both inhibit papain-like cysteine proteases161718

The viral serpin crmA is a suppressor of the inflammatory response through inhibition of IL-1 and IL-18 processing by the cysteine protease caspase-1.19 In eukaryotes, a plant serpin has been shown to inhibit metacaspases. It is presently unclear whether any mammalian serpins function to inhibit caspases in vivo.

Localisation and roles

Figure 3: The hormone cortisol bound to the serpin corticosteroid-binding globulin.20

Approximately two thirds of human serpins perform extracellular roles. For example, extracellular serpins regulate the proteolytic cascades central to blood clotting (antithrombin), the inflammatory response (antitrypsin, antichymotrypsin and C1 inhibitor) and tissue remodelling (PAI-1). Non-inhibitory extracellular serpins also perform important roles. Thyroxine-binding globulin and cortisol binding globulin transport the sterol hormones thyroxine and cortisol respectively (Figure 3).2120 The protease renin cleaves off a ten amino acid N-terminal peptide from angiotensinogen to produce the peptide hormone angiotensin I.22 Table 1 provides a brief summary of human serpin function as well as some of the diseases that result from serpin deficiency.

The first Intracellular members of the serpin superfamily were identified in the early 1990s.2324 As all nine serpins in Caenorhabditis elegans lack signal sequences, they are probably intracellular.25 Based upon these data it seems likely that the ancestral serpin to human serpins was an intracellular molecule.

The protease targets of intracellular inhibitory serpins have been more difficult to identify. Characterisation is complicated by these molecules appearing to perform overlapping roles, as well as the lack of precise functional equivalents of human serpins in model organisms such as the mouse. An important function of intracellular serpins may be to protect against the inappropriate activity of proteases inside the cell.26 For example, one of the best characterised human intracellular serpins is SERPINB9, which inhibits the cytotoxic granule protease granzyme B. In doing so, SERPINB9 may protect against inadvertent release of granzyme B and premature or unwanted activation of cell death pathways.27

Intracellular serpins also perform roles distinct from protease inhibition. For example, maspin, a non-inhibitory serpin, is important for preventing metastasis in breast and prostate cancers.2829 Another example is the avian nuclear cysteine protease inhibitor MENT, which acts as a chromatin remodelling molecule in avian red blood cells.3017

Phylogenetic studies show that most intracellular serpins belong to a single clade (see Table 1). Exceptions include the non-inhibitory heat shock serpin HSP47, which is a chaperone essential for proper folding of collagen and cycles between the cis-Golgi and the endoplasmic reticulum.31

Structure

Figure 4a: The X-ray crystal structure of native human antitrypsin (pdb code 1QLP).32 The five stranded A-sheet is in red, the six stranded B-sheet in green and the four stranded C-sheet in yellow. α-helices are shown in cyan. The RCL is at the top of the molecule in magenta. Two functionally important regions of the serpin, the breach and the shutter, are labelled. The figure was produced using PYMOL Figure 4b: The structure of native murine antichymotrypsin (pdb code 1YXA).33 Colouring is as for figure 4a. Note that two amino acids of the RCL are partially inserted into the top of the A β-sheet (in red).

Structural biology has played a central role in the understanding of serpin function and biology. Over eighty serpin structures, in a variety of different conformations (described below) have been determined to date. Although the function of serpins varies widely, these molecules all share a common structure (or fold).

The structure of the non-inhibitory serpin ovalbumin, and the inhibitory serpin antitrypsin revealed the archetype native serpin fold.3435 All typically have three β-sheets (termed A, B and C) and eight or nine α-helices (hA-hI) (see figure 4). Serpins also possess an exposed region termed the reactive centre loop (RCL) that in inhibitory molecules includes the specificity determining region and forms the initial interaction with the target protease. In antitrypsin, the RCL is held at the top of the molecule and is not pre-inserted into the A β-sheet (figure 4, left panel). This conformation commonly exists in dynamic equilibrium with a partially inserted native conformation36 seen in other inhibitory serpins (see figure 4, right panel).

Conformational change and inhibitory mechanism

Early studies on serpins revealed that the mechanism by which these molecules inhibit target proteases appeared distinct from the lock-and-key-type mechanism utilised by small protease inhibitors such as the Kunitz-type inhibitors (eg. Basic pancreatic protease inhibitor). Indeed, serpins form covalent complexes with target proteases.37 Structural studies on serpins also revealed that inhibitory members of the family undergo an unusual conformational change, termed the Stressed to Relaxed (S to R) transition.34363839 During this structural transition the RCL inserts into β-sheet A (in red in figure 4 and 5) and forms an extra (fourth) β-strand. The serpin conformational change is key to the mechanism of inhibition of target proteases.

When attacking a substrate, serine proteases catalyze peptide bond cleavage in a two-step process. Initially, the catalytic serine performs a nucleophilic attack on the peptide bond of the substrate (Figure 5). This releases the new N-terminus and forms an ester-bond between the enzyme and the substrate. This covalent enzyme-substrate complex is called an acyl enzyme intermediate. Subsequently, this ester bond is hydrolysed and the new C-terminus is released. The RCL of a serpin acts as a substrate for its cognate protease. However, after the RCL is cleaved, but prior to hydrolysis of the acyl-enzyme intermediate, the serpin rapidly undergoes the S to R transition. Since the RCL is still covalently attached to the protease via the ester bond, the S to R transition causes the protease to be moved from the top to the bottom of the serpin. At the same time, the protease is distorted into a conformation where the acyl enzyme intermediate is hydrolysed extremely slowly.9 The protease thus remains covalently attached to the target protease and is thereby inhibited. Further, since the serpin has to be cleaved to inhibit the target protases, inhibition consumes the serpin as well. Serpins are therefore irreversible enzyme inhibitors. The serpin mechanism of inhibition is illustrated in figure 5 and 6 and several movies illustrating the serpin mechanism can be seen at this link.

Mechanism of protease inhibition by serpins
Figure 5:
Left: Structure of the non-covalent complex between insect Serpin1K and inactive rat trypsin (pdb code 1K9O).40 To trap the encounter complex the trypsin (orange) was mutated to an inactive form unable to cleave the RCL. Serpin colouring is as for figure 4.
Right: Final complex between antitrypsin and active trypsin (pdb code 1EZX).9 The figure was produced using PYMOL.
Figure 6: Catalytic mechanism of serine proteases (adapted from Serine protease mechanism) illustrating the stage in the cycle that is trapped by serpin inhibitors (magenta circle). The ester bond in the acyl enzyme intermediate is highlighted in red.

Conformational modulation of serpin activity

The conformational mobility of serpins provides a key advantage over static lock and key protease inhibitors. In particular, the function of inhibitory serpins can be readily controlled by specific cofactors. The X-ray crystal structures of antithrombin, heparin cofactor II, MENT and murine antichymotrypsin reveal that these serpins adopt a conformation where the first two amino acids of the RCL are inserted into the top of the A β-sheet (see figures 4 and 7). The partially inserted conformation is important because co-factors are able to conformationally switch partially inserted serpins into a fully expelled form.4142 This conformational rearrangement makes the serpin a more effective inhibitor.

The archetypal example of this situation is antithrombin, which circulates in plasma in a partially inserted relatively inactive state. The primary specificity determining residue (the P1 Arginine) points towards the body of the serpin and is unavailable to the protease (Figure 7). Upon binding a high affinity heparin pentasaccharide sequence within long chain heparin, antithrombin undergoes a conformational change, RCL expulsion and exposure of the P1 Arginine. The heparin pentasaccharide bound form of antithrombin is thus a more effective inhibitor of thrombin and factor Xa (figure 7).4344 Furthermore, both of these coagulation proteases contain binding sites (called exosites) for heparin. Heparin therefore also acts as a template for binding of both protease and serpin, further dramatically accelerating the interaction between the two parties (Figure 7). After the initial interaction, the final serpin complex is formed and the heparin moiety is released. This interaction is physiologically important. For example, after injury to the blood vessel wall heparin is exposed, and antithrombin is thus activated to control the clotting response. The understanding of the molecular basis of this interaction formed the basis of the development of Fondaparinux, a synthetic form of Heparin pentasaccharide used as an anti-clotting drug.45

Figure 7:
From left to right.
1. The partially inserted conformation of native antithrombin. The P1 Arginine is in purple spheres (from pdb 2ANT).
2. Binding of the high affinity heparin pentasaccharide sequence (in cyan spheres) within long chain heparin (in yellow spheres) (from pdb 1TB6).
Note how the P1 Arginine residue has flipped to a more exposed position.
3. Initial interaction of thrombin (orange) with the RCL. Thrombin also contains a binding site for heparin (from pdb 1TB6).
4. Following docking, the final serpin enzyme complex is formed (illustrated using the antitrypsin / trypsin complex) and heparin is released (from pdb 1EZX).

Certain serpins spontaneously undergo the S to R transition as part of their function, to form a conformation termed the latent state (Figure 8). In latent serpins the first strand of the C-sheet has to peel off to allow full RCL insertion. Latent serpins are unable to interact with proteases and are not protease inhibitors. The transition to latency represents a control mechanism for the serpin PAI-1. PAI-1 is released in the inhibitory conformation, however, undergoes conformational change to the latent state unless it is bound to the cofactor vitronectin.46 Thus PAI-1 contains an "auto-inactivation" mechanism. Similarly, antithrombin can also spontaneously convert to the latent state as part of its normal function. Finally, the N-terminus of tengpin (see pdbs 2PEE and 2PEF), a serpin from Thermoanaerobacter tengcongensis, is required to lock the molecule in the native inhibitory state. Disruption of interactions made by the N-terminal region results in spontaneous conformational change of this serpin to the latent conformation.4748

Figure 8a: X-ray crystal structure of native PAI-1 (from pdb 1DVM) (stabilised though mutation). The RCL is in magenta, and the first β-strand of the C-β-sheet in yellow. In the absence of vitronectin, PAI-1 converts to the latent form (right) (from pdb 1LJ5). The first strand of the C-sheet has peeled off to allow full RCL insertion.
Figure 8b: Structure of native PAI-1 bound to vitronectin (in cyan) (from pdb 1OCO). Part of the RCL is disordered in this structure and is represented by a dashed line.

Serpin receptor interactions

In humans, extracellular serpin-enzyme complexes are rapidly cleared from circulation. One mechanism by which this occurs is the low density lipoprotein receptor related protein (LRP receptor), which binds to inhibitory complexes made by antithrombin, PA1-1 and neuroserpin, causing uptake and subsequent signalling events.49 Thus, as a consequence of the conformational change during serpin-enzyme complex formation, serpins may act as signalling molecules that alert cells to the presence of protease activity.49 The fate of intracellular serpin-enzyme complexes remains to be characterised.

Conformational change and non-inhibitory function

Certain non-inhibitory serpins also use the serpin conformational change as part of their function. For example the native (S) form of thyroxine-binding globulin has high affinity for thyroxine, whereas the cleaved (R) form has low affinity. Similarly, native (S) Cortisol Binding Globulin (CBG) has higher affinity for cortisol than its cleaved (R) counterpart (Figure 3). Thus, in these serpins, RCL cleavage and the S to R transition has been commandeered to allow for ligand release, rather than protease inhibition.502120

Serpins, serpinopathies and human disease

Serpins are peculiarly vulnerable to inactivating disease causing mutations that result in the formation of misfolded polymers or protein aggregates ("serpinopathies"). Well characterised serpinopathies include alpha 1-antitrypsin deficiency (alpha-1), which may cause familial emphysema and sometimes liver cirrhosis, certain familial forms of thrombosis related to antithrombin deficiency, types 1 and 2 hereditary angioedema (HAE) related to deficiency of C1-inhibitor and familial encephalopathy with neuroserpin inclusion bodies (FENIB; a rare type of dementia caused by neuroserpin polymerisation).1110 Serpins thus belong to a large group of molecules such as the prion proteins and the glutamine repeat containing proteins that cause proteopathies or conformational diseases.10

Serpin polymerisation causes disease in two ways. Firstly, the lack of active serpin results in uncontrolled protease activity and tissue destruction, this is seen in the case of antitrypsin deficiency. Secondly, the polymers themselves clog up the endoplasmic reticulum of cells that synthesize serpins, eventually resulting in cell death and tissue damage. In the case of antitrypsin deficiency, antitrypsin polymers cause the death of liver cells, sometimes resulting in liver damage and cirrhosis. The mechanism by which serpin polymers cause cell death remains to be fully understood.

Figure 9: Model illustrating the ideas behind the proposed A-sheet mechanism of serpin polymerisation.1151 The A β-sheet is in red. The RCL (magenta) of the orange molecule is inserted into the bottom of the A-sheet of the white molecule.

Like cleaved serpins, serpin polymers are hyperstable with respect to heating and each serpin monomer appears to have undergone the stressed to relaxed transition. Furthermore, serpin polymers are unable to inhibit target proteases, suggesting that the RCL is unavailable and inserted into the A-sheet. In the absence of definitive structural data, it was therefore postulated that serpins polymerise via a mechanism known as A-sheet polymerisation 11. In normal function the RCL inserts into the A β-sheet to form a fourth strand (figure 4). In the A-sheet polymerisation model, it was suggested that the RCL of one serpin molecule spontaneously inserted into the A-sheet of another, to form a long chain polymer (figure 9). In effect, it was thus proposed that polymerization occurred as a consequence of the requirement of the serpin scaffold to accept an additional β-strand.

Serpins were one of the first families for which disease-causing mutations were directly analyzed in reference to the available crystal structures.52 In support of the A-sheet polymerisation model, it was noted that many serpin mutations that cause polymerisation localise to two distinct regions of the molecule (highlighted in figure 4a) termed the shutter and the breach. The shutter and the breach contain highly-conserved residues, underlie the path of RCL insertion and are proposed to be important for conformational change.

Two structures of cleaved serpin polymers have been solved; both of which reveal RCL / A-sheet sheet linkages similar to those predicted by the A sheet polymerisation mechanism. 5354 However, in direct contrast to the known properties of physiological serpin polymers, crystals of cleaved serpin A-sheet polymers readily dissociate into monomeric forms. 5354

A large body of data now suggest that the events associated with serpin polymerisation occur during the folding of the molecule, and that mutations that cause serpinopathies interfere with the ability of the serpin to fold to the metastable native state.55 In normal serpin folding, the serpin rapidly moves through a key folding intermediate to attain the native state. Many studies have shown that it is the serpin folding intermediate that has the ability to polymerise, hence it is important that this folding species rapidly moves on to adopt native state. It was shown that mutations such as the Z-antitrypsin variant (Glu 342 to Lys) somehow prevented the final stage of seprin folding and caused the accumulation of the folding intermediate. Accordingly, population of the folding intermediate resulted in polymer formation.55 Interestingly, it was noted that once folded, the Z-antitrypsin variant closely resembles wild-type material in terms of thermal stability and inhibitory activity.55

Together these data have presented an important challenge to the A-sheet model for serpin polymerisation. On the one hand the idea that serpin polymer formation essentially takes advantage of the serpin mechanism of conformational change is an attractive one. On the other, the biophyiscal data in particular suggest that it is a folding intermediate (rather than the native form) that polymerises, and it is clear that this intermediate must have different structural properties to the native, folded state.

Figure 10: Model of a domain swapped serpin polymer.1 Both s5A and the RCL insert into the A-sheet of another serpin monomer.

In 2008, a key serpin crystal structure was determined that strongly suggests that physiological serpin polymers do not form via the A-sheet mechanism and instead form via a more extensive domain swapping event.1 The structure solved is of an antithrombin dimer (figure 1), and reveals that both strands s5A and the RCL are able to be incorporated into the A-sheet of another serpin molecule. This structure can readily be adapted to form long chain polymers (figure 10). 1

The new "domain swapped" model for serpin polymerisation reconciles the available biophysical and biochemical data. In particular, these data suggest that the final stage of serpin folding to the native state is most likely the incorporation of the fifth strand (s5A). Of key importance is the observation that several polymerogenic mutations (including the Z-variant) cluster on and around s5A and mutation of these residues may prevent proper incorporation of s5A into the A-sheet. As a result, during folding the mutation causes the serpin to remain "stuck" in the intermediate form. Much of the intermediate species, unable to efficiently form the native conformation, eventually forms hyperstable polymers via the insertion of both s5A and the RCL into another intermediate (figure 10).

Mutations that result in spontaneous formation of latent (or latent-like), inactive conformations

Figure 11: X-ray crystal structure of the δ-conformation of the Leucine 55 to Proline mutation of antichymotrypsin (from pdb 1QMN). Four residues of the RCL (magenta; dashed line indicates disordered region) are inserted into the top of the A β-sheet. Part of the F α-helix (cyan) has unwound and fills the bottom half of the A β-sheet.56

Certain pathogenic mutations in serpins can promote inappropriate transition to the monmoeric latent state (see figure 8a for the structure of the latent state). This causes disease because it reduces the amount of active inhibitory serpin. For example, the disease-linked antithrombin variants wibble and wobble,57 both promote formation of the latent state.

It is also worth highlighting a structure of a disease-linked human antichymotrypsin variant that further demonstrates the extraordinary flexibility of the serpin scaffold. The structure of antichymotrypsin (Leucine 55 to Proline) revealed a novel "δ" conformation that may represent an intermediate between the native and latent state (Figure 11). In the delta conformation four residues of the RCL are inserted into the top of β-sheet A. The bottom half of the sheet is filled as a result of one of the α-helices (the F-helix) partially switching to a β-strand conformation, completing the β-sheet hydrogen bonding.56 It is unclear whether other serpins can adopt this conformer, or whether this conformation has a functional role. However, it is speculated that the δ-conformation may be adopted by Thyroxine binding globulin during thyroxine release.21

Other mechanisms of serpin-related disease

In humans, simple deficiency of many serpins (e.g. through a null mutation) may result in disease (see Table 1).

Rarely, single amino acid changes in the RCL of a serpin alters the specificity of the inhibitor and allow it to target the wrong protease. For example, the Antitrypsin-Pittsburgh mutation (methionine 358 to arginine) allowed the serpin to inhibit thrombin, thus causing a bleeding disorder.58

Serpins are suicide inhibitors, the RCL acting as a "bait". Certain disease-linked mutations in the RCL of human serpins permit true substrate-like behaviour and cleavage without complex formation. Such variants are speculated to affect the rate or the extent of RCL insertion into the A-sheet. These mutations effectively result in serpin deficiency through a failure to properly control the target protease.5259

Several non-inhibitory serpins play key roles in important human diseases. Most notably, maspin functions as a tumour suppressor in breast and prostate cancer. The mechanism of maspin function remains to be fully understood. Murine knockouts of maspin are lethal; these data suggest that maspin plays a key role in development.60

Evolution

Serpins were initially believed to be restricted to eukaryote organisms, but have since been found in a number of bacteria and archaea.4561 It remains unclear whether these prokaryote genes are the descendants of an ancestral prokaryotic serpin or whether they are the product of lateral gene transfer (genetic transfer between organisms not by evolutionary descent). Rawlings et al., showed that serpins are the most widely distributed and largest family of protease inhibitors.7

Types of serpin

Human serpins

In 2001, a serpin nomenclature was established (see table 1, below).8 The naming system is based upon a phylogenetic analysis of ~500 serpins.4 The human genome encodes 16 serpin clades, termed serpinA through to serpinP, encoding 29 inhibitory and 7 non-inhibitory serpin proteins (see Law et al. (2006) for a recent review).62 The proteins are named serpinXY where X is the clade of the protein and Y the number of the protein within that clade. Table 1 lists each human serpin, together with brief notes in regards to each molecules function and the consequence (where known) of dysfunction or deficiency.

Table 1

Protein name PDB Common Name Description Disease / Effect of deficiency Chromosomal location
SERPINA1 1QLP
7API
1D5S
Alpha 1-antitrypsin extracellular, inhibits human neutrophil elastase.63 Deficiency results in emphysema, antitrypsin polymerisation results in cirrhosis. Serpinopathy.11 The C-terminal fragment of cleaved SERPINA1 may inhibit HIV-1 infection.64 14q32.1
SERPINA2 Antitrypsin-related protein extracellular, possible pseudogene65 Unknown 14q32.1
SERPINA3 1YXA
2ACH
Alpha 1-antichymotrypsin Extracellular, inhibits cathepsin G.66 Deficiency results in emphysema. Serpinopathy56 14q32.1
SERPINA4 Kallistatin extracellular, inhibition of kallikrein, regulation of vascular function67 Unknown 14q32.1
SERPINA5 2OL268
3B9F69
Protein C inhibitor Extracellular, inhibitor of active protein C.70 Intracellular role in preventing phagocytosis of bacteria.71 Male murine knockouts are infertile72 In multiple sclerosis, accumulation of PCI has been noted in chronic active plaques.73 14q32.1
SERPINA6 2V6D20
2VDX
2VDY
Cortisol binding globulin Extracellular, non-inhibitory; cortisol binding.20 Deficiency may cause chronic fatigue74 14q32.1
SERPINA7 2CEO21
2RIV
2RIW
Thyroxine-binding globulin extracellular, non-inhibitory; thyroxine binding21 Deficiency causes hypothyroidism.75 Xq22.2
SERPINA8 Angiotensinogen Extracellular; non-inhibitory, cleavage by renin results in release of angiotensin I.76 Variants linked to hypertension77 Murine knockouts result in hypotension.78 1q42-q43
SERPINA9 Centerin Extracellular; inhibitory, maintenance of naive B cells7980 Unknown 14q32.1
SERPINA10 Protein Z-related protease inhibitor extracellular, binds protein Z and inactivates factor Xa and factor XIa)81 Deficiency may cause venous thromboembolic disease82 14q32.1
SERPINA11 - probably extracellular, not characterised. Unknown 14q32.13
SERPINA12 Vaspin extracellular, insulin-sensitizing adipocytokine83 Unknown 14q32.1
SERPINA13 - probably extracellular, not characterised Unknown 14q32
SERPINB1 1HLE Monocyte neutrophil elastase inhibitor Intracellular, inhibition of neutrophil elastase84 Murine knockout results in neutrophil survival defect and immune deficiency85 6p25
SERPINB2 1BY7 Plasminogen activator inhibitor-2 Intracellular/extracellular. Inhibition of extracellular uPA. Intracellular function unclear, however, may protect against viral infection.86 Murine knockouts viable / no obvious phenotype87 18q21.3
SERPINB3 Squamous cell carcinoma antigen-1 (SCCA-1) Intracellular, inhibitor of papain-like cysteine proteases16 Unknown 18q21.3
SERPINB4 Squamous cell carcinoma antigen-2 (SCCA-2) Intracellular, inhibitor of cathepsin G and chymase88 Unknown 18q21.3
SERPINB5 1WZ9 Maspin intracellular, non inhibitory, tumour suppressor in breast and prostate cancer28 Murine knockouts lethal, important role in cancer metastasis60 18q21.3
SERPINB6 PI-6 intracellular, inhibition of cathepsin G89 Murine knockout reveals mild neutropenia90 6p25
SERPINB7 Megsin intracellular, involved in megakaryocyte maturation91 Unknown 18q21.3
SERPINB8 PI-8 intracellular; possible furin inhibitor92 Unknown 18q21.3
SERPINB9 PI-9 intracellular, inhibitor of the cytotoxic granule protease granzyme B93 murine knockout reveals immune dysfunction94 6p25
SERPINB10 Bomapin intracellular, unknown function95 Analysis of murine genomic material (C57/BL6; the common lab strain) reveals a stop codon in this gene (BC069938). In contrast, EST data suggests that full length bomapin is expressed in Czech II mice. These data suggest that loss of Bomapin function in mice does not result in an overt phenotype. 18q21.3
SERPINB11 intracellular, unknown function96 Murine Serpinb11 is an active inhibitor whereas the human orthalogue is inactive.96 18q21.3
SERPINB12 Yukopin intracellular, unknown function97 Unknown 18q21.3
SERPINB13 Hurpin/Headpin intracellular, inhibitor of papain-like cysteine proteases98 Unknown 18q21.3
SERPINC1 2ANT
2ZNH
1AZX
1TB6
2GD4
1T1F
Antithrombin Extracellular, inhibitor of coagulation, specifically factor X, factor IX and thrombin99 Deficiency results in thrombosis and other clotting disorders. Serpinopathy100 1q23-q21
SERPIND1 1JMJ
1JMO101
Heparin cofactor II extracellular, thrombin inhibitor102 Murine knockouts are lethal.103 22q11
SERPINE1 1DVN
1OC0
Plasminogen activator inhibitor 1 Extracellular; inhibitor of thrombin, uPA and TPa.104 Cardiovascular disease, tumour progression105106 7q21.3-q22
SERPINE2 Glia derived nexin / Protease nexin I Extracellular, inhibition of uPA and tPA.107 Abnormal expression leads to human male infertility.108 Knockout mice also develop epileptic phenotype.109 2q33-q35
SERPINF1 1IMV Pigment epithelium derived factor Extracellular, non-inhibitory, potent anti-angiogenic molecule.110 PEDF has been reported to bind the glycosaminoglycan hyaluronan. 111 Murine knockout studies reveal that PEDF regulates the vasculature and mass of the pancreas and the prostate.110 17p13.3
SERPINF2 2R9Y112 Alpha 2-antiplasmin extracellular, plasmin inhibitor, inhibitor of fibrinolysis.113 Bleeding disorder114 17pter-p12
SERPING1 2OAY Complement 1-inhibitor Extracellular, C1 esterase inhibitor.115 Angiodemia, serpinopathy.116 Several polymorphisms in the SERPING1 gene are strongly associated with development of age-related macular degeneration and blindness.117 11q11-q13.1
SERPINH1 47 kDa Heat shock protein (HSP47) intracellular, non inhibitory, molecular chaperone in collagen folding.118 Murine knockouts are lethal119 11p15
SERPINI1 1JJO Neuroserpin Extracellular, inhibitor of tPA, uPA and plasmin120 Mutated in dementia (FENIB). Serpinopathy121 3q26
SERPINI2 Pancpin Extracellular, unknown protease target.122 Studies on the Pequeño mouse line revealed that loss of SERPINI2 results in pancreatic insufficiency through pancreatic acinar cell loss.123 In addition a possible role for SERPINI2 in inhibition of pancreatic cancer metastasis has been suggested.122 3q26

Insect Serpins

The Drosophila melanogaster genome contains 29 serpin encoding genes. Amino acid sequence analysis has placed 14 of these serpins in serpin clade Q and 3 in serpin clade K with the remaining 12 serpins classified as orphan serpins not belonging to any clade.124 The clade classification system is difficult to use for Drosophila serpins and instead a nomenclature system has been adopted that is based on the position of Drosphila serpin genes on the Drosophila chromosomes. 13 of the Drosophila serpins occur as isolated genes in the genome (including Serpin-27A, see below), with the remaining 16 organised into three gene clusters that occur at chromosome positions 28D (2 serpins), 42D (5 serpins), 43A (4 serpins), 77B (3 serpins) and 88E (2 serpin).124125126

Drosophila serpin-27A

Studies on Drosophila serpins reveal that Serpin-27A inhibits the Easter protease (the final protease in the Nudel, Gastrulation Defective, Snake and Easter proteolytic cascade) and thus controls dorsoventral patterning. Easter functions to cleave Spätzle (a chemokine-type ligand), which results in toll mediated signaling. In addition to its central role in embryonic patterning, toll signalling is also important for the innate immune response in insects. Accordingly, serpin-27A additionally functions to control the insect immune response.127128129

Worm Serpins

The genome of the nematode worm C. elegans contains nine serpins, however, only five of these molecules appear to function as protease inhibitors.25 One of these serpins, SRP-6, has been shown to perform a protective function and guard against stress induced calpain-associated lysosomal disruption. Further SRP-6 functions to inhibit lysosomal cysteine proteases released after lysosomal rupture. Accordingly, worms lacking SRP-6 are sensitive to stress. Most notably, SRP-6 knockout worms die when placed in water (the hypo-osmotic stress lethal phenotype or Osl). Based on these data it is suggested that lysosomes play a general and controllable role in determining cell fate.130

Plant serpins

The presence of serpins in plants has long been recognised - indeed, barley Z serpin is the major protein component in beer. The genome sequence of Arabidopsis thaliana is predicted to encode 29 serpins. Plant serpins are able to inhibit serine proteases in vitro. However, the absence of close relatives of chymotrypsin-like proteases in plants suggests that these molecules may instead perform an alternative function. Indeed, Arabidopsis serpin1 inhibits metacaspase-like proteases in vivo and may control cell death pathways.131

Fungal serpins

A single fungal serpin has been characterized to date: celpin from Piromyces sp. strain E2. Piromyces is an anaerobic fungus found in the gut of ruminants and is important for digesting plant material. Celpin is predicted to be an inhibitory molecule and contains two N-terminal dockerin domains in addition to the serpin domain. Dockerins are commonly found in proteins that localise to the fungal cellulosome, a large extracellular mulitprotein complex that breaks down cellulose6. It is therefore suggested that celpin protects the cellulosome against plant proteases. Interestingly certain bacterial serpins also localize to the cellulosome 132.

Prokaryote serpins

Predicted serpin genes are sporadicly distributed in prokaryotes. In vitro studies on some of these moelcules have revealed that they are able to inhibit proteases and it is suggested that they function as inhibitors in vivo. Interestingly, several prokaryote serpins are found in extremophiles. Accordingly, and in contrast to mammalian serpins, these molecule possess elevated resistance to heat denaturation.133134 The precise role of most bacterial serpins remains obscure, however, Clostridium thermocellum serpin localises to the cellulosome. It is suggested that the role of cellulosome-associated serpins may be to prevent unwanted protease activity against the cellulosome.132

Viral serpins

Serpins are also expressed by viruses as a way to evade the host's immune defense.135 In particular, serpins expressed by pox viruses, including cow pox (vaccinia) and rabbit pox (myxoma), are of interest because of their potential use as novel therapeutics for immune and inflammatory disorders as well as transplant therapy. 136137 A study on Serp1 reveals this molecule suppresses the Toll-mediated innate immune response and allows indefinite cardiac allograft survival in rats. 138136Studies on Crma and Serp2, reveal both are cross-class inhibitor and targets both serine (Granzyme B; albeit weakly) and cysteine proteases (Caspase 1 and Caspase 8).139140 In comparison to their mammalian counterparts, viral serpins contain significant deletions of elements of secondary structure. Specifically, structural studies on crmA reveals this molecule lacks the D-helix as well as significant portions of the A- and E-helices.141

See also

References

  1. ^ a b c d e Yamasaki M, Li W, Johnson DJ, Huntington JA (October 2008). "Crystal structure of a stable dimer reveals the molecular basis of serpin polymerization". Nature. doi:10.1038/nature07394. PMID 18923394. 
  2. ^ R. Carrell and J. Travis. (1985). "α1-Antitrypsin and the serpins: Variation and countervariation". Trends Biochem. Sci. 10: 20–24. doi:10.1016/0968-0004(85)90011-8. 
  3. ^ Hunt LT, Dayhoff MO (1980). "A surprising new protein superfamily containing ovalbumin, antithrombin-III, and α1-proteinase inhibitor". Biochem Biophys Res Commun. 95 (2): 864–71. doi:10.1016/0006-291X(80)90867-0. PMID 6968211. 
  4. ^ a b c Irving JA, Pike RN, Lesk AM, Whisstock. (2000). "Phylogeny of the Serpin Superfamily: Implications of Patterns of Amino Acid Conservation for Structure and Function". Genome Res. 10: 1845–64. doi:10.1101/gr.GR-1478R. PMID 11116082. 
  5. ^ a b Irving J, Steenbakkers P, Lesk A, Op den Camp H, Pike R, Whisstock J (2002). "Serpins in prokaryotes". Mol Biol Evol 19 (11): 1881–90. PMID 12411597. 
  6. ^ a b Steenbakkers PJ, Irving JA, Harhangi HR, et al (August 2008). "A serpin in the cellulosome of the anaerobic fungus Piromyces sp. strain E2". Mycol. Res. 112 (Pt 8): 999–1006. doi:10.1016/j.mycres.2008.01.021. PMID 18539447. 
  7. ^ a b Rawlings ND, Tolle DP, Barrett AJ. (2004). "Evolutionary families of peptidase inhibitors". Biochem J. 378: 705–16.. doi:10.1042/BJ20031825. PMID 14705960. 
  8. ^ a b Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, Gettins PG, Irving JA, Lomas DA, Luke CJ, Moyer RW, Pember